Cargando…

Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer

INTRODUCTION: HER2 overexpression, or rather HER2 gene amplification, is indicative for Herceptin therapy in both metastatic and pre-metastatic breast cancer patients. Patient's individual sensitivity to Herceptin treatment, however, varies enormously and spans from effectual responsiveness ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sassen, Andrea, Diermeier-Daucher, Simone, Sieben, Manuela, Ortmann, Olaf, Hofstaedter, Ferdinand, Schwarz, Stephan, Brockhoff, Gero
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750111/ https://www.ncbi.nlm.nih.gov/pubmed/19624808 http://dx.doi.org/10.1186/bcr2339

Ejemplares similares

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
por: Wege, Anja Kathrin, et al.
Publicado: (2018)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
por: Wege, Anja Kathrin, et al.
Publicado: (2020)

The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease
por: Brockhoff, Gero, et al.
Publicado: (2017)

Target HER four in breast cancer?
por: Brockhoff, Gero
Publicado: (2019)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting
por: Miles, David W
Publicado: (2001)

Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice
por: Bruss, Christina, et al.
Publicado: (2022)

Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer
por: Buiga, Petronela, et al.
Publicado: (2019)

IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)
por: Wege, Anja K, et al.
Publicado: (2016)

Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
por: Albert, Veruschka, et al.
Publicado: (2022)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
por: Swofford, Brenen P., et al.
Publicado: (2017)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
por: Wege, Anja Kathrin, et al.
Publicado: (2021)

Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
por: Mineo, J-F, et al.
Publicado: (2004)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
por: Gomez Marti, Juan Luis, et al.
Publicado: (2023)

Psoriasis Induced by Trastuzumab (Herceptin®)
por: Kim, Dae Hun, et al.
Publicado: (2013)

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2010)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice
por: Rom-Jurek, Eva-Maria, et al.
Publicado: (2018)

Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability
por: Kang, Se Hun, et al.
Publicado: (2008)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2016)

The role of Herceptin in early breast cancer
por: Subramanian, Ashok, et al.
Publicado: (2008)

Herceptin in clinical use - early 2000
por: Vogel, CL
Publicado: (2000)

Mild hyperthermia influence on Herceptin(®) properties
por: Escoffre, Jean-Michel, et al.
Publicado: (2015)

The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin
por: Lai, Hung-Wen, et al.
Publicado: (2012)

3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells
por: Ahmad, Aamir, et al.
Publicado: (2013)

Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticles
por: Shirshahi, Vahid, et al.
Publicado: (2013)

Phosphodiesterase Type 5 Inhibitors Increase Herceptin Transport and Treatment Efficacy in Mouse Metastatic Brain Tumor Models
por: Hu, Jinwei, et al.
Publicado: (2010)

Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin
por: Trojanec, R, et al.
Publicado: (2011)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
por: Müller, Volkmar, et al.
Publicado: (2018)

Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
por: Menendez, Javier A, et al.
Publicado: (2007)

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vi1ied0sgklrlahifq24ndcjvt